Members Login
Medical News Feed
EPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Drug details for : IMIGRAN RECOVERY
| Drug class description : | Analgesics: Selective 5-HT1 receptor agonists. |
| Generic Name : | Sumatriptan |
| Drug description : | Film-coated tablet. Pink, film-coated, capsule shaped, biconvex tablets debossed with 'GX ES3' on one side. |
| Presentation : | 50 mg, film-coated tablets. 50 mg sumatriptan base (as the succinate salt). |
| Indications : | Imigran Recovery is indicated for the acute relief of migraine attacks, with or without aura. Imigran Recovery should only be used where there is a clear diagnosis of migraine. |
| Adult Dosage : | Adults (18-65 years of age) The recommended dose is a single 50 mg tablet that should be swallowed whole with water. It is advisable that Imigran Recovery be taken as soon as possible after the onset of a migraine headache although it is effective at whatever stage of the headache it is taken. If there is a response to the first tablet but the symptoms recur, a second tablet may be taken. However, this must be at least 2 hours after the first tablet. No more than two 50 mg tablets (total dose 100 mg) may be taken in any 24 hour period or to treat the same attack. If there is no response to the first tablet, a second tablet should not be taken for the same attack. |
| Child Dosage : | Children and Adolescents (under 18 years of age) Not to be used in children or adolescents under 18 years of age. The safety and effectiveness of Imigran Recovery in children have not been established. |
| Elderly Dosage : | Elderly (over 65 years of age) Not to be used in those over 65 years of age. Experience of the use of Imigran Recovery in patients over 65 years is limited. |
| Contra Indications : | Imigran Recovery must not be used prophylactically. Hypersensitivity to any component of the preparation or to sulphonamides. Previous myocardial infarction, or those who have ischaemic heart disease, coronary vasospasm (Prinzmetal's angina), cardiac arrhythmias, peripheral vascular disease or symptoms or signs consistent with ischaemic heart disease. History of cerebrovascular accident (stroke) or transient ischaemic attack (TIA / ministroke). Known hypertension. Hepatic or renal impairment. History of seizures or other risk factors which lower the seizure threshold. Concurrent treatment with the following medications is contra-indicated: • Ergotamine or derivatives of ergotamine (including methysergide) (See Interactions). • Monoamine oxidase inhibitors (MAOIs). Imigran Recovery must not be used within 2 weeks of discontinuation of therapy with MAOIs. • Any 5-HT1 receptor agonist (triptan). Imigran Recovery is not to be used to treat the following rare variants of migraine: • Hemiplegic migraine – migraine with aura including unilateral motor weakness. • Basilar migraine – migraine with aura symptoms originating from the brain stem and/or both hemispheres such as double vision, difficulty in articulating words, clumsy and unco-ordinated movements, tinnitus, reduced level of consciousness. • Ophthalmoplegic migraine – migraine headache with involvement of one or more ocular cranial nerves resulting in weakness of the muscles controlling eye movement. |
| Special Precautions : | Imigran Recovery should only be used where a clear diagnosis of migraine has been made by a doctor or a pharmacist. For pharmacy supply, patients should have an established pattern of migraine (a history of five or more migraine attacks occurring over a period of at least 1 year). Imigran Recovery should not be taken concomitantly with other migraine therapies containing any triptan, ergotamine or derivative of ergotamine. If a migraineur fails to respond to the first tablet of Imigran Recovery, the attack may be treated with simple analgesics. Further, the diagnosis of migraine should be reconsidered with a doctor. The recommended dose of Imigran Recovery should not be exceeded. Migraineurs whose typical headaches persist for longer than 24 hours should seek advice from their doctor. Migraineurs in whom the pattern of symptoms has changed, or whose attacks have become more frequent, more persistent, or more severe, or who do not recover completely between attacks, should seek advice from their doctor. Anyone with atypical symptoms which include, but are not limited to, unilateral motor weakness, double vision, clumsy and unco-ordinated movements, tinnitus, reduced level of consciousness, seizure-like movements, or recent onset of rash with headache should seek advice from their doctor. Patients whose migraine symptoms appear for the first time after age 50 should seek advice from their doctor as there may be a more serious underlying cause. Migraineurs who experience four or more migraine attacks per month should be referred to a doctor for ongoing management. It should be noted that migraineurs may be at risk of certain cerebrovascular events (e.g. cerebrovascular accident, transient ischaemic attack). Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness that may be intense and involve the throat (See Adverse Reactions). Typically, such symptoms develop within 30 minutes of treatment and last for less than 2 hours. Where such symptoms are thought to indicate ischaemic heart disease, medical evaluation should be obtained immediately and no further doses of Imigran Recovery should be taken until considered appropriate by a doctor. Imigran Recovery should not be used by migraineurs in whom unrecognised cardiac disease is likely without a prior risk assessment by a doctor or pharmacist (See Contraindications). Special consideration should be given to postmenopausal women and men over 40. Risk factors for heart disease include hypercholesterolaemia, regular smoking, marked obesity, diabetes or a family history of early heart disease (father/brother developed heart disease before the age of 55, mother/sister developed heart disease before the age of 65). Anyone who has three or more of these risk factors is not suitable for pharmacy supply of sumatriptan. These evaluations may not identify everyone who has cardiac disease and, in very rare cases, serious cardiac events have occurred without underlying cardiovascular disease. There have been rare postmarketing reports describing patients with transient weakness, hyper-reflexia and incoordination following use of a selective serotonin reuptake inhibitor (SSRI) with sumatriptan. If concomitant use is considered to be appropriate, migraineurs should be warned to see their doctor if they develop weakness and incoordination following treatment. Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John's wort (Hypericum perforatum). Patients with known hypersensitivity to sulphonamides may exhibit an allergic reaction following administration of sumatriptan. Reactions may range from cutaneous hypersensitivity to anaphylaxis. Although evidence of cross-sensitivity is limited, treatment with Imigran Recovery is contraindicated in these patients (See Contraindications). Women with migraine who are taking the combined oral contraceptive have an increased risk of stroke and should seek advice from their doctor if migraine attacks started recently (within the last 3 months), migraine symptoms have worsened or they have migraine with aura. As with other acute migraine treatments, chronic daily headache/exacerbation of headache have been reported with overuse of sumatriptan and this may necessitate a drug withdrawal. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. |
| Interactions : | Studies in healthy subjects show that sumatriptan does not interact with propranolol, flunarizine, pizotifen or alcohol. Sumatriptan has the potential to interact with MAOIs, ergotamine and derivatives of ergotamine. The increased risk of coronary vasospasm is a theoretical possibility and therefore concomitant administration with MAOIs and ergotamines is contraindicated (See Contraindications). Prolonged vasospastic reactions have been reported with ergotamine. As these effects may be additive, 24 hours should elapse before sumatriptan can be taken following any ergotamine-containing preparation. Conversely, ergotamine-containing preparations should not be taken until 6 hours have elapsed following sumatriptan administration. Rarely, an interaction may occur between sumatriptan and SSRIs (See Special Precautions). There is a risk of pharmacodynamic interaction between sumatriptan and tricyclic antidepressants. Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John's wort (Hypericum perforatum). Pregnancy and lactation Imigran Recovery is not to be used in pregnancy or when breastfeeding unless on the advice of a doctor. Post-marketing data from the use of sumatriptan during the first trimester in over 1,000 women are available. Although these data contain insufficient information to draw definitive conclusions, they do not suggest an increased risk of congenital defects. Experience with the use of sumatriptan in the second and third trimester is limited. Evaluation of experimental animal studies does not indicate direct teratogenic effects or harmful effects on peri- and postnatal development. However, embryofoetal viability might be affected in the rabbit. It has been demonstrated that following subcutaneous administration, sumatriptan is excreted into breast milk. Infant exposure can be minimised by avoiding breast feeding for 24 hours after treatment. |
| Adverse Reactions : | Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common >1/10), common >1/100, <1/10), uncommon >1/1000, <1/100), rare >1/10,000, <1/1000) and very rare (<1/10,000) including isolated reports. Immune System Disorders Very rare: Hypersensitivity reactions ranging from cutaneous hypersensitivity to rare cases of anaphylaxis. Nervous System Disorders Common: Tingling, dizziness, drowsiness. Very rare: Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent. Nystagmus, scotoma. Eye Disorders Very rare: Flickering, diplopia, reduced vision. Loss of vision (usually transient). However, visual disorders may also occur during a migraine attack itself. Cardiac Disorders Very rare: Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, myocardial infarction (see Contraindications, Special Warnings and special precautions for use). Vascular Disorders Common: Transient increases in blood pressure arising soon after treatment. Flushing. Very rare: Hypotension, Raynaud's phenomenon. Gastrointestinal Disorders Common: Nausea and vomiting occurred in some patients but the relationship to sumatriptan is not clear. Very rare: Ischaemic colitis. Musculoskeletal and Connective Tissue Disorders The following symptom is usually transient and may be intense and can affect any part of the body including the chest and throat: Common: Sensations of heaviness. General Disorders and Administration Site Conditions The following symptoms are usually transient and may be intense and can affect any part of the body including the chest and throat: Common: Pain, sensations of heat, pressure or tightness. The following symptoms are mostly mild to moderate in intensity and transient: Common: Feelings of weakness, fatigue. Investigations Very rare: Minor disturbances in liver function tests have occasionally been observed. |
| Manufacturer : | GlaxoSmithKline |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org